Offering New Hope to Cancer Patients and Their Caregivers
A New Frontier in Cancer Therapy What makes us a life-changing biotech
Technology Based on Pancreatic Enzyme Therapy
Our long-term therapy is based on a pancreatic proenzyme formulation that suppresses tumor recurrence and metastasis.
How Our Technology WorksHalting Cancer Cells’ Ability to Invade and Metastasize
PRP, our lead candidate, controls cancer cell migration, inhibits tumor blood vessel formation and triggers the cell’s death.
How PRP WorksLatest Developments
Propanc Biopharma Initiates Development of Bio-Analytical Assay in Preparation for Human Trials
Propanc Biopharma Commences Drug Discovery Research Collaboration
Significant Market Opportunity for Cancer Therapy
80% of all cancers are solid tumors. We are initially targeting pancreatic, ovarian and colorectal tumors.
View the market need for solid tumorsStock Information
OTCQB: PPCB
Propanc Biopharma, Inc.
Change
Volume
Day Range
52 Week Range
BIO CEO & Investor Conference Presentation
